Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Dec 2023

Canaud Guillaume, Lopez Gutierrez Juan Carlos, Irvine Alan D, Vabres Pierre, Hansford Jordan R, Ankrah Nii, Branle Fabrice, Papadimitriou Athanasia, Ridolfi Antonia, O'Connell Paul, Turner Stuart, Adams Denise M

Abstract excerpt

PURPOSE: PIK3CA-related overgrowth spectrum (PROS) encompasses several rare conditions resulting from activating variants in PIK3CA. Alpelisib, a PI3Kα-selective inhibitor, targets the underlying etiology of PROS, offering a novel therapeutic approach to current management strategies. This study evaluated the safety and efficacy of alpelisib in pediatric and adult patients with PROS. METHODS: EPIK-P1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Thiazoles

Source

Identifiers

PMID: 37634128
DOI: 10.1016/j.gim.2023.100969

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).PMID 37634128Read ↗

PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With AlpelisibSemantic proximity Read ↗

Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum.Semantic proximity Read ↗

Response to Alpelisib in Clinically Distinct Pediatric Patients With PIK3CA -related Disorders.Semantic proximity Read ↗

Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndromeSemantic proximity Read ↗

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrumSemantic proximity Read ↗

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.Semantic proximity Read ↗

Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North AmericaSemantic proximity Read ↗

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.Semantic proximity Read ↗

Radiological Evaluation of the Natural History of PIK3CA-Related Overgrowth Spectrum (PROS)Semantic proximity Read ↗

The emerging role of PI3K inhibitors for solid tumour treatment and beyond.Semantic proximity Read ↗

Somatic PIK3R1 mutations in the iSH2 domain are accessible to PI3Kα inhibition.Semantic proximity Read ↗

PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.